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Abstract
The inflammasomes are innate immune system receptors/sensors that regulate the activation of 
caspase-1 and induce inflammation in response to infectious microbes and molecules derived from 
host proteins. It has been implicated in a host of inflammatory disorders. Recent developments 
have greatly enhanced our understanding of the molecular mechanisms by which different 
inflammasomes are activated. Additionally, increasing evidence in mouse models, supported by 
human data, strongly implicates an involvement of the inflammasome in the initiation or 
progression of diseases with a high impact on public health such as metabolic disorders and 
neurodegenerative diseases. Finally, recent developments pointing toward promising therapeutics 
that target inflammasome activity in inflammatory diseases have been reported. This review will 
focus on these three areas of inflammasome research.
INTRODUCTION
Inflammation is a protective immune response mounted by the evolutionarily-conserved 
innate immune system to harmful stimuli, such as pathogens, dead cells, or irritants, and is 
tightly regulated by the host. Insufficient inflammation can lead to persistent infection of 
pathogens while excessive inflammation can cause chronic or systemic inflammatory 
diseases. Innate immune function depends upon recognition of pathogen-associated 
molecular patterns (PAMPs), derived from invading pathogens, and danger-associated 
molecular patterns (DAMPs), induced as a result of endogenous stress, by germline-encoded 
pattern-recognition receptors (PRRs). Activation of PRRs by PAMPs or DAMPs triggers 
downstream signaling cascades and leads to production of type I interferon (interferon-α and 
interferon-β) and proinflammatory cytokines. Of note, DAMP-triggered inflammation, 
which is particularly important in inflammatory diseases, is termed sterile inflammation 
when it occurs in the absence of any foreign pathogens1.
Activation of the inflammasome is a key function mediated by the innate immune system, 
and recent advances have greatly increased our understanding of the macromolecular 
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activation of inflammasomes. Several families of PRRs are important components in the 
inflammasome complex including the nucleotide-binding domain, leucine-rich repeat 
containing proteins (NLRs, also known as NOD-like receptors) and absent in melanoma 2-
like receptors (ALRs, AIM2-like receptors) in both mice and humans2. Upon sensing certain 
stimuli, the relevant NLR or AIM2 can oligomerize to be a caspase-1-activating scaffold. 
Active caspase-1 subsequently functions to cleave the proinflammatory IL-1 family of 
cytokines into their bioactive forms, IL-1β and IL-18, and cause pyroptosis, a type of 
inflammatory cell death3,4.
Inflammasomes have been linked to a variety of autoinflammatory and autoimmune 
diseases, including neurodegenerative diseases (multiple sclerosis, Alzheimer’s disease, and 
Parkinson’s disease) and metabolic disorders (atherosclerosis, type-2 diabetes, and obesity)4. 
In inflammatory disease initiation, inflammasomes play either causative or contributing 
roles, and also exaggerate the pathology in response to host-derived factors. This review will 
focus on the current understanding of inflammasome activation, the roles of inflammasomes 
in several prevalent diseases that are increasingly recognized as having an inflammatory 
contribution, such as neurodegenerative diseases and metabolic disorders, and advances in 
potential therapies targeting inflammasomes.
MECHANISMS OF INFLAMMASOME ACTIVATION
General principles of inflammasome activation
Recent developments in our understanding of the mechanisms of inflammasome activation 
have been expertly reviewed in depth4–8. However, here, we give a brief overview of recent 
advances in the mechanisms of inflammasome activation in order to best explain their link 
with disease.
Inflammasomes are multimeric protein complexes that assemble in the cytosol after sensing 
PAMPs or DAMPs7,9. While there are fundamental differences between inflammasomes 
dependent upon stimuli, in general, canonical inflammasomes serve as a scaffold to recruit 
the inactive zymogen pro-caspase-1 (Figures 1 and 2). Oligomerization of pro-caspase-1 
proteins induces their auto-proteolytic cleavage into active caspase-110. Active caspase-1 is 
a cysteine-dependent protease that cleaves precursor cytokines pro-IL-1β and pro-IL-18 
generating biologically active cytokines IL-1β and IL-18, respectively11–13. Active 
caspase-1 is also able to induce an inflammatory form of cell death known as pyroptosis5–7.
Inflammasome names denote the protein forming the scaffold. Most inflammasomes are 
formed with one or two NLR family members, and NLRC4 requires interaction with an 
NLR member of the NAIP subfamily of proteins6,14 (Figures 1 and 2A). However, non-NLR 
proteins such as AIM2 (Figure 2B) and pyrin can also form inflammasomes. NLRC4 can 
directly associate with caspase-1 through CARD-CARD interactions15. NLRs containing an 
amino-terminal pyrin domain (PYD) are shown to associate with apoptosis-associated 
speck-like protein containing a CARD (ASC) in order to recruit pro-caspase-1 to the 
inflammasome9,16 (Figures 1).
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Inflammasome activation occurs when the scaffold protein senses or binds its activating 
stimuli. How this occurs is starting to be clarified for certain inflammasome proteins6, 
prominent among these are the roles of ASC, AIM2, and NAIP/NLRC4. For example, AIM2 
can directly bind to its stimulus, double-stranded DNA (dsDNA)17. However, many 
questions remain regarding inflammasome activation. We will now briefly discuss the 
mechanism of activation of the most well-characterized inflammasomes where major 
advances have been made. The readers can refer to recent reviews where all of the NLR 
inflammasomes have been reviewed5–7, including evidence supporting the existence of less-
characterized inflammasomes, such as NLRP6, NLRP7, NLRP12, and IFI16 
inflammasomes. Additionally, though NLRP1, which has many genetic variants in mice and 
rats, forms well-defined inflammasomes in these rodent models, activation of the single 
human NLRP1 paralog into an inflammasome is less well understood18.
NLRP3 inflammasome
The NLRP3 inflammasome (Figure 1) is activated in response to the widest array of stimuli, 
leading to the theory that the dissimilar agonists induce similar downstream events which 
are sensed by NLRP38,19,20. The mechanisms of NLRP3 activation supported by the most 
studies include potassium efflux out of the cell, the generation of mitochondrial reactive 
oxygen species (ROS), translocation of NLRP3 to the mitochondria, the release of 
mitochondrial DNA or cardiolipin, or the release of cathepsins into the cytosol after 
lysosomal destabilization6–8 (Figure 1). However, not all of these events are induced by all 
NLRP3 agonists, so the precise mechanism of NLRP3 activation is still debated. 
Additionally, increases in intracellular calcium can activate the NLRP3 inflammasome21,22, 
but this is also not a requirement of all NLRP3 agonists23. Though many published studies 
support the involvement of lysosomal cathepsins, proteases that degrade internalized 
proteins, in NLRP3 inflammasome activation, it is important to note that this is not without 
some controversy24.
In most cell types, NLRP3 must be primed, and a prototypical example of such a priming 
event is the binding of LPS to TLR4. Priming has long been known to increase cellular 
expression of NLRP3 through NF-κB signaling25. However, recent findings have shown 
that priming rapidly licenses mouse NLRP3 inflammasome activation by inducing the 
deubiquitination of NLRP3 independent of new protein synthesis, while inhibition of 
deubiquitination inhibits human NLRP3 activation26,27. Once primed, NLRP3 can respond 
to its stimuli and assemble the NLRP3 inflammasome. Additionally, ASC must be linearly 
ubiquitinated for NLRP3 inflammasome assembly28. Current stimuli recognized as NLRP3 
agonists that induce NLRP3 inflammasome formation include ATP, pore-forming toxins, 
crystalline substances, nucleic acids, hyaluronan, and fungal, bacterial, or viral pathogens6,7. 
These stimuli can be encountered during infection, either produced by pathogens or released 
by damaged host cells. Additionally, pathologic conditions in the body may promote 
formation of these stimuli in the absence of infection, such as the formation of inflammatory 
cholesterol crystals, as discussed in more detail later.
Recent studies identified that the NLRP3 NBD oligomerizes the NLRP3 PYD, which serves 
as a scaffold to nucleate ASC proteins through PYD-PYD interactions29,30. This causes 
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ASC to convert to a prion-like form and generate long ASC filaments that are crucial to 
inflammasome activation. Pro-caspase-1 then interacts with ASC through CARD-CARD 
interactions and forms its own prion-like filaments that branch off of the ASC filaments. The 
close proximity of pro-caspase-1 proteins then induces auto-proteolytic maturation of pro-
caspase-1 into active caspase-1.
Additionally, increasing evidence has identified a crucial role for caspase-8 in 
inflammasome activation and pro-IL-1β processing. Caspase-8 is a pro-apoptotic protease 
that initiates the external apoptosis pathway in response to external stimuli, such as FasL and 
TNF, and protects against an inflammatory form of cell death termed necroptosis31. It is 
now also recognized that caspase-8 is required for both the transcriptional priming and 
activation of the canonical and noncanonical NLRP3 inflammasomes in mice in response to 
pathogenic stimuli and ligands stimulating various different TLRs32–34. Thus, inflammatory 
diseases in which TLR ligands are generated could lead to caspase-8-mediated NLRP3 
priming or activation.
Additionally, caspase-8 was shown to bind and localize to ASC specks, further suggesting 
that caspase-8 is an important component of inflammasome complexes35. However, the 
exact molecular mechanism of how caspase-8 promotes caspase-1 activation has yet to be 
elucidated. Importantly, caspase-8 also has an identified role in NLRC4 and AIM2 
inflammasome activation35,36 and has even been shown to directly promote pro-IL-1β 
processing in a noncanonical caspase-8 inflammasome induced by the binding of certain 
extracellular pathogens to dectin-137. Notably, the exact role of caspase-8-mediated 
inflammasome activation is somewhat controversial38.
NLRC4 inflammasome
In contrast to the diverse stimuli that activate NLRP3, the NLRC4 inflammasome responds 
to a more limited set of stimuli. A major advance in our understanding of the NLRC4 
inflammasome is that NLRC4 forms a complex with various NAIP proteins, and NLRC4-
activating ligands are bound by these NAIP components rather than by NLRC4 (Figure 2A). 
This raises the question of whether NLRC4 is a scaffolding protein and not a receptor14,39. 
In mice, NAIP1 binds the bacterial type III secretory system (T3SS) needle protein40,41, 
NAIP2 binds the bacterial T3SS rod protein42, and both NAIP5 and NAIP6 bind bacterial 
flagellin42,43. T3SS is found in several gram negative bacteria and allows the bacteria to 
inject effector molecules into infected host cells. By contrast to mice, only one human NAIP 
protein has been characterized, and it was found to bind only the T3SS needle protein40, 
suggesting a far more restrictive repertoire of ligands for the NLRC4 inflammasome in 
human cells than NLRP3, which responds to a plethora of stimuli.
Once NAIP proteins bind their ligands, they can oligomerize with NLRC4 and form a NAIP/
NLRC4 inflammasome14. In order for NLRC4 to be activated, its autoinhibition must be 
relieved to allow oligomerization with NAIP proteins, but how this occurs is unclear14. 
However, two new gain-of-function mutations have recently been identified in humans that 
cause severe spontaneous autoimmune syndrome, suggesting that the helical domain is 
responsible for this autoinhibition44,45. Though some reports indicate that mouse NLRC4 
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must be phosphorylated prior to inflammasome activation46,47, there are also conflicting 
reports indicating that phosphorylation is dispensable14.
Though NLRC4 contains a CARD domain, ASC is required for maximal inflammasome 
activation7 (Figure 2A). A possible explanation might be the formation of NLRC4 filaments, 
as there is evidence that the CARD domain can convert ASC to its prion-like form31.
AIM2 inflammasome
The non-NLR AIM2 can also form a caspase-1-containing inflammasome, but, unlike the 
NLRs, the HIN-200 domain of AIM2 can directly bind its stimulus, cytosolic dsDNA, which 
may be encountered in the cytosol during pathogenic infection (Figure 2B)17. The 
autoinhibitory conformation of AIM2 is created by interactions of its two domains and 
relieved by the sugar phosphate backbone of dsDNA48. DNA binding displaces the PYD 
domain48, freeing the PYD domain to recruit ASC to the complex17,49. AIM2 cannot 
interact with ASC unless autoinhibition is relieved50 and, thus, AIM2 maintains itself in an 
inactive state until its ligand binds.
Interestingly, AIM2 does not appear to recognize a specific sequence or structure of dsDNA 
but instead requires a dsDNA strand of at least 80 base pairs for optimal inflammasome 
activation48. Similar to NLRP3, oligomerized AIM2 nucleates ASC through PYD-PYD 
interactions and converts ASC to its prion form, leading to the development of long PYD-
PYD ASC filaments29,30.
Recently, a noncanonical AIM2 inflammasome was shown to mediate protection against 
Francisella novicida51. F. novicida infection is detected by cGAS and STING, inducing the 
expression of the transcription factor IRF1. IRF1 increases the expression of guanylate 
binding proteins, which increase the intracellular killing of the bacterium. This releases 
dsDNA into the cytosol and induces AIM2 inflammasome activation.
Noncanonical inflammasomes
A developing area of interest in the inflammasome field is the noncanonical inflammasome 
formed by caspase-11 in mice (Figure 2C). Caspase-11 was initially found to be important 
for the activation of caspase-1 and caspase-352. Recently, it was shown that caspase-11 
promotes NLRP3 inflammasome activation to indirectly enhance processing of pro-IL-1β or 
pro-IL-1853. More remarkably, caspase-11 detects intracellular LPS and some intracellular 
bacteria, directly mediating cell death and IL-1α secretion, but not IL-1β secretion, in a 
mechanism independent of the traditional LPS receptor TLR47,54,55. Though humans do not 
express caspase-11, recent studies indicate that caspase-4 and caspase-5 in human cells serve 
a similar function56,57 (Figure 2C). Notably, active caspase-4 can promote the activation of 
the primed NLRP3 inflammasome without a need for a canonical NLRP3 activating 
stimulus57. As caspase-11-deficient mice are protected from endotoxic shock53, further 
study of the noncanonical inflammasome in human cells is of great interest.
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Mechanisms of inflammasome spreading
ASC has long been recognized to redistribute upon inflammasome activation from the 
nucleus to the cytosol and form a large perinuclear aggregate in cells58,59. In a recent 
breakthrough, ASC specks were reported to be released by dying cells, leading to cleavage 
of extracellular pro-IL-1β and activating caspase-1 in macrophages internalizing the 
specks60. Importantly, as activation of all major inflammasomes is associated with speck 
formation59, this suggests that inflammasome activation propagates inflammation from cell 
to cell. The buildup of specks at sites of inflammation has serious implications for 
inflammatory diseases, as injection of purified ASC specks into mice in vivo was shown to 
propagate inflammation60.
Additionally, phosphorylation of ASC was recently identified to be a key checkpoint in ASC 
speck formation. The kinases Syk and JNK, which activate in response to a vast array of 
stimuli and lead to the phosphorylation of many downstream targets, mediate 
phosphorylation of ASC upon NLRP3 inflammasome activation, and inhibition of these 
kinases prevented ASC speck formation and blocked caspase-1 activation61. Importantly, 
phosphorylation was dispensable for NLRP3 and ASC oligomerization. This suggests that 
phosphorylation of ASC may be necessary for ASC to switch to its prion form and form 
self-propagating filaments. This also suggests that kinase inhibition may have potential 
therapeutic use against inflammatory diseases in the absence of more targeted inhibitors.
INFLAMMASOMES IN DISEASE
Here we focus on neurologic disorders and metabolic diseases, both of which are not 
traditionally considered to be inflammatory diseases, but are increasingly recognized as 
having an inflammatory component that contributes significantly to the disease process. 
Misfolded protein aggregates and aberrant accumulation of certain metabolites accompanied 
with those diseases are endogenous DAMPs that have been proved to be direct activators of 
the NLRP3 inflammasome, which plays a critical role in the initiation and progress of those 
diseases.
The inflammasome and multiple sclerosis
Multiple sclerosis (MS), one of the most common autoimmune/inflammatory diseases, is 
characterized by myelin-reactive CD4+ T cells that infiltrate the central nervous system 
(CNS), attack oligodendrocytes and induce demyelination62. Demyelination partially 
disrupts the communication of the nervous system, resulting in physical, mental, and 
psychiatric challenges, among other issues. Presently, MS has no cure and shortens the 
lifespan of patients approximately 5 to 10 years63.
Experimental autoimmune encephalomyelitis (EAE) is a commonly-used animal model to 
mimic MS. To induce EAE, mice are immunized with the peptide myelin oligodendrocyte 
glycoprotein (MOG) emulsified in adjuvant, inducing infiltration of MOG-specific T cells 
and other inflammatory cells into the CNS64.. Prior to the discovery of NLRs, the 
inflammasome products caspase-1, IL-1β, and IL-18 had been shown to contribute to EAE 
progression. Casp1−/−, Il1a−/−, Il1b−/− and Il18−/− mice are resistant to EAE, accompanied 
by reductions in IFN-γ and/or IL-17 levels65–67. Recently, Nlrp3 expression has been shown 
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to increase in the spinal cord during EAE progression and Nlrp3-deficient mice showed a 
dramatically delayed course and reduced severity of disease, accompanied by fewer 
infiltrating inflammatory cells and reduced astrogliosis64,68. In addition, a study using a 
cuprizone model of MS also showed that Nlrp3-deficient mice had delayed demyelination 
and oligodendrocyte loss69. Additionally, in EAE mice there was increased IL-18 levels, 
compared with controls and Il18-deficient mice phenocopied the reduced disease seen in 
Nlrp3-deficient mice, suggesting NLRP3 functions through IL-18 to promote EAE64,68.
Despite these findings, the role of NLRP3 in EAE progression is complicated. Expression of 
Nlrp3 in antigen-presenting cells (APCs) was required to stimulate T helper type 1 (Th1) 
and Th17 cells to respond to brain autoantigen in one study64. Additionally, Nlrp3 and Asc 
(also known as Pycard) deficiency caused reduced expression of many chemokines and 
chemokine receptors, such as Ccr2 and Ccr6, in both APCs and Th cells, reducing migration 
of Th1 and Th17 cells into the CNS of Nlrp3- and Asc-deficient mice following EAE 
induction by MOG peptide immunization. However, direct delivery of CD4+ T cells from 
EAE-induced WT, Nlrp3−/− or Asc−/− mice into the brain and spinal cord of recipient 
Rag2−/− mice, which lack mature T cells, induced the same extent of disease68. In summay, 
while these results suggest that the NLRP3 inflammasome contributes to both Th1 and Th17 
cell responses and migration during EAE, the function of the NLRP3 inflammasome is not 
an inherent function of T cells. In the clinic, peripheral blood mononuclear cells (PBMCs) 
from relapsing-remitting MS patient had higher levels of NLRP3, IL-1β, and caspase-1 than 
were found in PBMCs from healthy controls. Intriguingly, soluble factors secreted by 
human PBMCs upon NLRP3 activation skew the cytokine profile of CD4+ T cells toward a 
pro-inflammatory Th17 phenotype, supporting a link between MS and the NLRP3 
inflammasome70.
However, a role for NLRP3 and ASC in EAE is not found by all studies and varies with 
variations in the disease model. Aggressive immunization of mice with heat-killed 
mycobacteria (Mtb) was able to induce EAE even in the absence of NLRP3 or ASC, 
whereas lower-dose Mtb immunization required NLRP3 and ASC for EAE induction71. 
Another study found no difference in MOG-induced EAE disease between WT and Nlrp3-
deficient mice. In the same study, ASC promoted EAE progression in an inflammasome-
independent manner through a mechanism of maintaining CD4+ T cell survival. In 
agreement with this, Asc-deficient mice were even more resistant to EAE than Casp1-
deficient mice72. Part of the differences in inflammasome dependency may be explained by 
recent findings showing that IFN-β inhibited IL-1β production by macrophages, and only 
NLRP3-dependent EAE was ameliorated by IFN-β treatment. This suggests that IFN-β may 
therapeutically inhibit the NLRP3 inflammasome-IL-1β/IL-18 axis in MS71. Though IFN-β 
has been used therapeutically for more than 15 years, one third of MS patients fail to 
respond to IFN-β, echoing heterogeneity in the disease.
In addition to the NLRP3 inflammasome, a recent study using the pertussis toxin (PTX)-
induced EAE model showed that TLR4 was required for pro-IL-1β induction, and the pyrin-
dependent inflammasome contributed to bioactive IL-1β formation. IL-1β stimulated nearby 
stromal cells to secret IL-6, which can promote leukocyte adhesion and migration. Pyrin 
(also known as Mefv)-deficient 2D2 mice (MOG-specific T cell receptor transgenic mice) 
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had lower EAE incidence and delayed and less severe disease following PTX injection. 
However, the pyrin inflammasome only functions at the initial stage of EAE induced by 
PTX, as comparable infiltration of CD3+ cells was observed in the spinal cord of mice with 
similar clinical scores regardless of their genotype. In line with this, adoptive transfer of 
MOG-specific T cells into WT and pyrin-deficient mice induced similar EAE73.
The inflammasome and Alzheimer’s disease
Accumulation of amyloid-β plaques in the cerebrum is a characteristic of Alzheimer’s 
disease (AD) Amyloid-β peptide is regularly formed in cerebral tissue by cleavage of the 
amyloid precursor protein, but it can form prion-like misfolded oligomers in the case of 
AD74. Amyloid-β was the first molecule associated with neurodegenerative disease models 
that was found to activate the murine NLRP3 inflammasome, resulting in IL-1β 
production75. Fibrillary amyloid-β induces NLRP3-inflammasome-dependent caspase-1 
activation through a mechanism dependent on endosomal rupture and cathepsin B release in 
LPS-primed murine macrophages75 (Figure 3). Interestingly, administration of cathepsin B 
inhibitors significantly improved memory deficit and reduced amyloid plaque load in the 
brain in the AD mouse model, suggesting a potential therapeutic approach for Alzheimer’s 
treatment in which the inflammasome is targeted76. Importantly, a recent pivotal study in 
mice identified that the cell-surface receptor CD36 mediates the internalization of soluble 
amyloid-β, which then undergoes intracellular conversion to fibrillary amyloid-β to activate 
the NLRP3 inflammasome77. A direct link between the NLRP3 inflammasome and the 
development of AD has been shown in APP/PS1 mice (transgenic mice developing chronic 
deposition of amyloid-β) with NLRP3 and caspase-1 deficiency. These mice have reduced 
AD-related pathogenesis, reflected by reduced chronic amyloid-β secretion, neuronal 
inflammation, and cognitive impairment. In these mice, NLRP3-inflammasome deficiency 
skewed microglial cells to an M2 phenotype (characterized by elevated expression of 
arginase-1 and IL-4 ), resulting in the reduced deposition of amyloid-β and enhanced tissue 
remodeling in the AD mouse model78. In addition to the mouse study, a recent study found 
enhanced active caspase-1 expression in human brains with AD, suggesting that there is a 
link between inflammasome activation and Alzheimer’s in humans78. Therefore, in vitro and 
in vivo studies suggest a potentially important role for the NLRP3 inflammasome in the 
pathogenesis of AD and identify the NLRP3-caspase-1 axis as a potential target for AD 
therapy.
Inflammasome and Parkinson’s disease model
Parkinson’s disease (PD) results in the death of dopamine-generating neurons in the 
substantia nigra and the presence of aggregated inclusions mainly composed of α-synuclein 
(αSyn) in neurons79. αSyn can form fibrils with a cross β-sheet structure, morphologically 
similar to the amyloid fibrils from AD80. Through multiple mechanisms, intracellular αSyn 
can be released into extracellular spaces81. Extracellular αSyn activates primary microglia, 
astrocytes, as well as transformed microglia and astrocyte cell lines and induces the 
production of the cytokine IL-1β81,82. In a rat model of PD, chronic expression of 
exogenous IL-1β introduced in an adenoviral vector in the region of the substantia nigra was 
shown to induce cell death in dopamine neurons and to promote PD progression83. Recently 
it was found that both fibrillary and monomeric αSyn induce pro-IL-1β expression via TLR2 
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signaling in human primary monocytes, but only fibrillary αSyn fully activated the 
inflammasome by inducing caspase-1 activation and mature IL-1β production84. This 
activation of caspase-1 required phagocytosis, cathespin B, and ROS. Cathepsin B and ROS 
are thought to lie upstream of NLRP3 activation, suggesting that αSyn activated the NLRP3 
inflammasome84. However, this study did not use the more relevant microglial cells and 
astrocytes, and the involvement of NLRP3 was not directly proven by an in vivo animal 
model.
In a PD model mouse in which PD is induced by loss of nigral dopaminergic neurons caused 
by treatment with neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), mice 
lacking Nlrp3 are resistant to developing PD. This provides in vivo evidence for a link 
between the NLRP3 inflammasome and PD85. Interestingly, dopamine was found to 
negatively regulate NLRP3 activation in both primary microglia and astrocytes via a 
dopamine D1 receptor (DRD1)-cyclic adenosine monophosphate (cAMP) signaling 
pathway85. Moreover, cAMP was found to directly bind to NLRP3 and promote its 
ubiquitination-dependent degradation via the E3 ubiquitin ligase MARCH785. Furthermore 
mice lacking DRD1 are more susceptible to MPTP-induced neuroinflammation, reflected by 
enhanced NLRP3 activation-dependent IL-1β and IL-18 production and increased loss of 
dopaminergic neurons85. These studies suggest that dopamine-producing neurons and the 
NLRP3 inflammasome regulate each other in a bidirectional fashion, where the 
inflammasome can damage these neurons, while dopamine from these neurons can inhibit 
NLRP3 function.
NLRP3 inflammasome and atherosclerosis
Chronic inflammation plays an essential role in the initiation and progression of metabolic 
disorders such as type 2 diabetes (T2D), obesity, gouty arthritis, and atherosclerosis86. 
Atherosclerosis accounts for 70% of morbidity in T2D patients and is a chronic disease that 
results in progressive narrowing of arterial vessels due to imbalanced lipid metabolism. 
Cholesterol crystals and white blood cells accumulate on the arterial wall, limiting the flow 
of oxygen-rich blood to the organs87. It is commonly referred to as a hardening or furring of 
the arteries, which can lead to life-threatening complications such as heart attack and stroke.
It has long been suggested, on the basis of evidence from mouse models88–90, that IL-18, a 
product of inflammasome activation, may have crucial roles in the initiation and progression 
of atherosclerosis. Furthermore, human atherosclerotic plaques have elevated concentrations 
of IL-18 and IL-18 receptors compared to disease-free arterial tissues. Apolipoprotein E 
(ApoE) is important for proper cholesterol metabolism. In ApoE-deficient mice, which 
spontaneously develop atherosclerotic lesions, elevated IL-18 levels have been shown to 
cause vascular inflammation and enhance the instability of atherosclerotic plaques, while 
IL-18-deficiency resulted in reduced atherosclerotic lesion size89,91,92. Elevation of low 
density lipoprotein (LDL) and free fatty acids (FFAs) in human blood due to imbalanced 
lipid metabolism is able to induce pro-IL-1β production through TLRs, providing the first 
signal for inflammasome activation93 (Figure 4A). Recent studies indicate that the cell 
surface receptor CD36 facilitates internalization of oxidized LDL (ox-LDL) and intracellular 
conversion of ox-LDL to cholesterol crystals77. These cholesterol crystals formed 
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intracellularly activate the NLRP3 inflammasome in vitro in both mouse and human cells 
through phagolysosomal damage, a mechanism dependent on both cathepsin B and 
cathepsin L88 (Figure 4A). In vivo, intraperitoneal injection of cholesterol crystals in mice 
induced acute inflammation that was attenuated by the deficiency of NLRP3 inflammasome 
components, cathepsin B, and cathepsin L. In this model, IL-1β was released through 
NLRP3 inflammasome activation and in turn promoted rupture of atherosclerotic plaques.
Mice lacking the LDL receptor are prone to developing atherosclerotic plaques. When these 
mice are fed a high-cholesterol diet, they have markedly reduced lesion size if the bone 
marrow cells lack Nlrp3, Asc, or Il1a and Il1b88. Similarly, in the ApoE-deficient mouse 
model of atherosclerosis, lack of IL-1β significantly decreases the size of atherosclerotic 
lesions94. In line with this, another study showed that blockade of IL-1β inhibited 
atherosclerotic plaque formation in the ApoE-deficient mouse model95. However, other 
studies have failed to link NLRP3 and IL-1β to atherosclerosis but instead found that IL-1α 
played an essential role in mice96,97. Further studies are required to clarify the contributions 
of IL-1α and IL-1β to atherogenesis.
NLRP3 inflammasome and type 2 diabetes
Type 2 diabetes (T2D) is a major global health threat resulting in insulin resistance and is a 
chronic inflammatory disease characterized by elevated circulating levels of TNF, 
interleukins, and cytokine-like proteins known as adipokines released from adipose tissue98. 
IL-1β in particular has been strongly linked to the pathogenesis of T2D by promoting insulin 
resistance and causing β-cell functional impairment and apoptosis. In cell culture, IL-1β 
dampens insulin sensitivity by inducing JNK-dependent serine phosphorylation of insulin 
receptor substrate-1 (IRS-1), resulting in the disruption of insulin-induced PI3K-Akt 
signaling in insulin-targeted cells. At the same time, IL-1β induces the expression of TNF-
α99, which could independently impair insulin signaling100. Together with elevated FFAs in 
circulation due to imbalanced lipid metabolism, IL-1β induces metabolic stressors, such as 
ER stress and oxidative stress, both of which are involved in induction of inflammation and 
β-cell loss, thereby leading to the pathogenesis of T2D86,101. Furthermore, clinical trials 
reported that either IL-1 receptor antagonist (IL-1RA) or anti-IL-1β neutralizing antibody 
improved control of glucose levels and β-cell function102,103. Data also show that fatigue in 
T2D patients was reduced by IL-1β blockade. Trials with larger patient numbers should 
strengthen the argument for IL-1β-targeted therapy in T2D104.
Elevation of NLRP3 inflammasome activity in myeloid cells from T2D patients when 
compared with those from unaffected individuals has been described105. Multiple studies 
have found that NLRP3-, ASC-, and/or caspase-1-deficient mice show improved glucose 
tolerance and insulin sensitivity when exposed to a high fat diet (HFD)99,106–109. This is 
accompanied by reduced inflammatory cytokine levels in the serum and metabolic tissues 
such as liver and adipose tissue in conjunction with increased insulin-PI3K-Akt 
signaling99,106–108. These studies provide a direct link between the NLRP3 inflammasome, 
chronic inflammation, and insulin resistance.
As regards the role of the NLRP3 inflammasome and IL-1β in T2D pathogenesis, extensive 
studies have identified endogenous and exogenous stimulators of the NLRP3 inflammasome 
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during T2D. Islet amyloid polypeptide (IAPP), a 37-amino-acid peptide hormone secreted 
from β-cells along with insulin, can form an amyloid structure that builds up in the 
pancreatic islets of patients with T2D110. As in the conversion of oxLDL to cholesterol 
crystals, the surface receptor CD36 also facilitates the conversion of soluble IAPP to its 
amyloid form (Figure 4B). In vitro, IAPP induces NLRP3 activation through a mechanism 
involving phagolysosome perturbation as well as cathepsin-B and cathepsin-L that leads to 
IL-1β production in macrophages and dendritic cells in culture111 (Figure 4B). In a 
transgenic mouse model in which human IAPP is overexpressed in mouse β-cells, pancreatic 
macrophages showed strong induction of IL-1β111,112. Elevated blood glucose was reported 
to induce IL-1β expression in β-cells, possibly through inflammasome activation mediated 
by thioredoxin (TRX)-interacting protein (TXNIP)108,113. Glucose can upregulate TXNIP 
expression in islets, and increased ROS due to oxidative stress in T2D has been proposed to 
cause conformational changes in TXNIP, leading to dissociation from thioredoxin and, in 
turn, association with NLRP3 for inflammasome activation108 (Figure 4B). Even though 
those studies could link oxidative stress with NLRP3 activation and IL-1β production in 
islets, the data were not reproducible in Txnip-deficient macrophages by another research 
group111.
The neuromodulatory lipids known as endocannabinoids were recently found to induce 
NLRP3 inflammasome-dependent IL-1β production by pancreatic infiltrating macrophages 
through the peripheral CB1 receptor (CB1R), resulting in pancreatic β-cell death in a 
paracrine manner114 (Figure 4B). Endocannabinoid anandamide increased ASC protein 
levels and caspase-1 activation in rat islets and markedly increased IL-1β secretion from a 
mouse macrophage cell line, RAW264.7. Anandamide-induced IL-1β production is 
dependent on Nlrp3 and Cb1r (also known as Cnr1). Intriguingly, blockade of CB1R by an 
inhibitor delayed the progress of T2D in the Zucker diabetic fatty rat which carries a 
spontaneous mutation of the leptin receptor gene and develops hyperglycemia progressively 
with aging accompanied by reduced β-cell apoptosis and hyperglycemia. This finding 
implicates CB1R to be a therapeutic target in T2D114.
Finally saturated fatty acids such as palmitate and ceramide that arise from a high fat diet 
and induce type 2 diabetes can induce NLRP3 inflammasome activation99,107 (Figure 4B). 
In mouse macrophages, palmitate inhibits AMP-activated protein kinase (AMPK) activity, 
leading to defective autophagy and the generation of mitochondrial ROS, which is a 
proposed mechanism of NLRP3 inflammasome activation99. Ceramide is also sensed by 
NLRP3 resulting in NLRP3-dependent caspase-1 activation in both mouse bone marrow-
derived macrophages (BMDM) and mouse epididymal adipose tissue explants107. 
Interestingly, replacement of saturated fatty acid (SFA) with monounsaturated fatty acid 
(MUFA) in HFDs improves insulin sensitivity by reducing IL-1β production via preserved 
AMPK activity in the mouse model115. Recently, omega 3 fatty acids (ω-3 FAs) which are 
polyunsaturated fatty acids, have been shown to inhibit NLRP3 inflammasome activity 
through a G protein-coupled receptor (GPR120)/GPR40-β-arrestin-2 signaling pathway116. 
More importantly, ω-3 FAs prevented insulin resistance in a HFD-induced T2D model, 
suggesting the potential dietary use of ω-3 FAs in the amelioration of T2D and other 
inflammatory diseases116. Using the human THP-1 cell line, others have shown that 
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unsaturated fatty acid can prevent NLRP3 activation, presenting another way to reduce 
inflammation117.
NLRP3 inflammasome and obesity
Obesity is characterized by excessive expansion of adipose tissue due to adipocyte 
hypertrophy and immune cell infiltration98. Obesity-associated inflammation leads to 
functional abnormality of adipocytes, resulting in elevated circulating levels of FFAs and 
ectopic lipid accumulation118. This can subsequently give rise to multiple metabolic 
disorders such as atherosclerosis and T2D, as discussed previously. In this section, we will 
focus on discussing the involvement of inflammasome components in the development of 
obesity and adipose inflammation.
The expression of human NLRP3 and ASC/PYCARD is upregulated in adipocytes from 
obese patients119. Caspase-1 expression was found in both human and mouse adipose tissues 
and increases with adipocyte differentiation and obesity development120. Blockade of 
caspase-1 and IL-1β, but not IL-18, improves adipogenic gene expression in vitro, indicating 
that caspase-1 regulates adipogenesis potentially via IL-1β. Differentiated adipocytes with 
caspase-1 deficiency also have improved adipogenesis and insulin sensitivity compared to 
wild-type control cells. 120.
To establish the direct link between inflammasome activity and obesity development, HFD- 
or genetically-induced obese animals lacking inflammasome components have been 
studied106,120. It was initially reported that caspase-1 contributes to adipose tissue 
formation, as mice lacking Casp1 have reduced adipocyte size, reduced fat mass, increased 
adipogenic gene expression and improved insulin sensitivity. Furthermore in the HFD-
induced obesity model, mice lacking Casp1 gained less weight than wild-type controls did. 
In the spontaneously obese mouse model (ob/ob mice), caspase-1 inhibition reduced the 
body weight of ob/ob mice. Interestingly, caspase-1 blockade resulted in decreased 
lipogenesis and higher fat oxidation than in control mice but did not affect food intake, 
suggesting the potential mechanism by which caspase-1 promotes obesity120. Similarly, it 
was also observed that NLRP3, ASC, and caspase-1 deficiency protected from HFD-induced 
obesity106. However, a recent study reported contradictory results that mice lacking Casp1 
were more obese than control mice including having increased fat mass compared with 
controls121. The difference may be due to the variation in intestinal microbiota in mice 
raised in different animal facilities, as intestinal microbiota has been demonstrated to play a 
significant role in metabolic diseases122. Additionally, IL-18, one of the products of 
inflammasome activation, has been shown to protect mice from obesity as mice lacking Il18 
developed obesity due to increased food intake123. This provides another possibility for the 
discrepancy in obesity phenotypes observed in Casp1-deficient mice.
Recently, it was shown that the lack of inhibitor of κB kinase epsilon (IKBKE), a 
downstream mediator of TLR and cytokine signals, in ApoE-deficient mice fed a Western-
type diet (high in saturated fat) caused enhanced expression of inflammasome-related genes 
and low-grade chronic inflammation124. Hence, IKBKE functions as an endogenous 
negative regulator of the NLRP3 inflammasome under an obesity-inducing condition.
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As regards the role of caspase-1 in obesity, studies have shown that it is likely that caspase-1 
contributes to obesity through various mechanisms. It was previously thought that 
macrophages accumulate within inflamed adipose tissue to produce caspase-1125. However, 
recent studies in mice have shown that a major source of caspase-1 in adipose tissue is 
independent of infiltrating macrophages120. Recently, caspase-1 was shown to prevent lipid 
clearing in non-hematopoietic cells by an NLRP3-dependent but IL-1α/β- and IL-18-
independent manner126. Furthermore, sirtuin 1 (SIRT1), a deacetylase which can regulate 
metabolism and protect from obesity, was recently shown to be a caspase-1 substrate. 
Adipocyte-specific Sirt1 knockout resulted in spontaneous obesity, and SIRT1 protein was 
cleaved and inactivated in adipose tissues by active caspase-1 under the HFD stress127. 
However, the mechanism of inflammasome and caspase-1 activation in adipocytes needs 
clarification.
A strong association between obesity and leukocytosis exists, and inflamed adipose tissue 
from obese mice was recently found to induce monocytosis in recipient wild type mice128. 
NLRP3 played an essential role in obesity-induced leukocytosis, as Nlrp3−/− bone marrow 
reconstituted in ob/ob recipient mice resulted in significantly-reduced numbers of circulating 
leukocytes128.
THERAPIES THAT TARGET INFLAMMASOMES
Inappropriate inflammasome activity has been incriminated in the pathogenesis of 
neurodegenerative disease and metabolic disorders. Many reagents that target the 
inflammasome products IL-1β and IL-18, including recombinant IL-1RA anakinra, the 
neutralizing IL-1β antibody canakinumab, the soluble decoy IL-1 receptor rilonacept, IL-18–
binding protein, soluble IL-18 receptors and anti-IL-18 receptor monoclonal antibodies, 
have been developed to treat autoinflammatory diseases such as cryopyrin-associated 
autoinflammatory syndrome (CAPS)129,130. However, independently of IL-1β and IL-18, 
inflammasome-dependent pyroptosis is a type of inflammatory cell death that will release 
DAMPs to induce more inflammation and also is important in the pathology of CAPS131. 
Therefore, inhibitors of the inflammasomes could offer greater therapeutic promise for this 
condition.
A small-molecule inhibitor, named glyburide, that is commonly used for treatment of T2D 
was the first compound identified to inhibit NLRP3- but not NLRC4- and NLRP1-
dependent IL-1β production132. Glyburide is able to inhibit ATP-, nigericin-, and IAPP-
induced NLRP3 inflammasome activation111. However, glyburide’s mechanism of action 
remains elusive, though it is known to function downstream of the P2X7 receptor and 
upstream of NLRP3. Importantly, glyburide has been shown to efficiently prevent 
endotoxic-shock-induced lethality in the animal model of this disease132. A recently 
identified group of NLRP3 inhibitors targeting P2X7 signaling is the nucleoside reverse 
transcriptase inhibitors (NRTIs), which are mainly used to block retrovirus replication. 
NRTIs have efficacy on several inflammatory and autoimmune diseases in mouse 
models133. Several other small-molecule inhibitors targeting NLRP3, NLRP1, NLRC4 or 
AIM2, including parthenolide134, Bay 11–708134, CRID3135, auranofin136, 
isoliquiritigenin137, 3,4-methylenedioxy-β-nitrostyrene138, cyclopentenone prostaglandin 
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15d-PGJ2139 and 25-Hydroxycholesterol (25-HC)140, have been characterized, even though 
their potency for in vivo usage needs more evaluation. The large majority of these are 
pharmacologic inhibitors that have been repurposed to target the inflammasome.
Recently, two additional small-molecule inhibitors that reduced NLRP3 activation have 
been reported. It was found that the ketone body β-hydroxybutyrate (BHB), which serves as 
an alternative source of ATP during energy-deficit status, specifically inhibits a variety of 
stimuli triggering NLRP3 inflammasome activation but not NLRC4 or AIM2 inflammasome 
activation141. Importantly, in animal models of NLRP3-mediated diseases such as Muckle-
Wells syndrome, familial cold autoinflammatory syndrome, and urate crystal-induced 
peritonitis, BHB-complexed nanolipogels and a ketogenic diet strikingly attenuated 
caspase-1 activation and IL-1β secretion. It was shown that BHB inhibits the NLRP3 
inflammasome by preventing potassium efflux and reducing ASC oligomerization and speck 
formation, although the direct target of BHB is still under exploration141.
Another study found that the compound MCC950 is a highly selective inhibitor of the 
NLRP3 inflammasome142. MCC950 blocked both canonical (ATP, nigericin, and 
monosodium urate) and noncanonical (cytosolic LPS) NLRP3-dependent inflammasome 
activation at nanomolar concentrations, with no effect on NLRC4, NLRP1, or AIM2 
inflammasomes. In vivo, MCC950 has been shown to reduce IL-1β production and attenuate 
the severity of EAE, a disease model of multiple sclerosis described earlier which is known 
to be exacerbated by the NLRP3 inflammasome64,68,71. MCC950 rescued the neonatal 
lethality in a mouse model of CAPS while blockade of IL-1β alone did not prevent lethality, 
providing evidence for a benefit of inflammasome inhibitors beyond the sole inhibition of 
IL-1β. Even though the mechanism of NLRP3 inhibition by MCC950 is not fully 
understood, an extensive assessment of in vitro and in vivo pharmacokinetics of MCC950 
has been performed, making significant strides toward therapeutic application142.
Type I interferon has been shown to suppress inflammasome activation with a poorly 
understood mechanism143. Recent studies showed that an IFN-stimulated gene product 
cholesterol 25-hydroxylase (Ch25h) antagonizes both Il1b transcription and NLRP3, 
NLRC4, and AIM2 inflammasome activation, suggesting Ch25h has a broad inhibitory 
activity of different inflammasomes. More importantly, the Ch25h substrate 25-
hydroxycholesterol is able to inhibit NLRP3 inflammasome activation and IL-1β 
production140.
CONCLUSIONS AND PERSPECTIVES
The new understanding of how inflammasomes are activated in health and disease raises 
new questions. Can post-translational modifications of inflammasome components be 
targeted to modulate inflammasome activation? For example, therapies that specifically 
promote NLRP3 ubiquitination could quell pathologic inflammation driven by NLRP3 
inflammasome activation by promoting NLRP3 degradation. What are the contributory roles 
of inflammasomes in the myeloid lineage compared to other cell types such as endothelial 
cells, epithelial cells or even adipocytes in inflammatory diseases? Can drugs that directly 
target inflammasome components, rather than those that target the end products of 
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inflammasomes such as IL-1β, be identified? Two new gain-of-function mutations of 
NLRC4, Val341Ala and Thr337Ser, causing severe spontaneous autoimmune syndromes 
have recently been identified in humans44,45. Establishment of the mouse model with similar 
mutations in NLRC4 will be a powerful tool to study the mechanism of NLRC4 auto-
activation-induced autoimmune diseases and evaluate NLRC4 inhibitors in vivo.
Importantly, a greater understanding of the balance between beneficial versus detrimental 
inflammasome activation is also needed. Indeed, inflammasome activity is critical for host 
response to microbial pathogens and possibly for optimal response to vaccine adjuvants, as 
cytokine production by the innate immune system shapes the adaptive immune response. 
Thus, all inflammasome activation cannot be considered harmful, and the therapeutic 
inhibition of this pathway has to be balanced against its beneficial contribution. As the 
mechanistic insight of the inflammasomes increases, opportunities to create new therapies 
for patients with inflammatory diseases are expected to enhance proportionately.
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Figure 1. Mechanisms of NLRP3 inflammasome activation
NLRP3 must be primed before activation. Priming involves two distinct steps. First, an NF-
κB–activating stimulus, such as LPS binding to TLR4, induces elevated expression of 
NLRP3 (as well as IL1B), which leads to increased expression of NLRP3 protein. 
Additionally, priming immediately licenses NLRP3 by inducing its deubiquitination. The 
adaptor protein ASC must become linearly ubiquitinated and phosphorylated for 
inflammasome assembly to occur. After priming, canonical NLRP3 inflammasome 
activation requires a second, distinct signal to activate NLRP3 and lead to the formation of 
the NLRP3 inflammasome complex. The most commonly accepted activating stimuli for 
NLRP3 include relocalization of NLRP3 to the mitochondria, the sensation of mitochondrial 
factors released into the cytosol (mitochondrial ROS, mitochondrial DNA, or cardiolipin), 
potassium efflux through ion channels, and cathepsin release following destabilization of 
lysosomal membranes. Recent studies have determined that activated NLRP3 nucleates ASC 
into prion-like filaments through PYD-PYD interactions. Pro-caspase-1 filaments 
subsequently form off of the ASC filaments through CARD-CARD interactions, allowing 
autoproteolytic activation of pro-caspase-1. Inset shows domain arrangement of the NLRP3 
inflammasome components. Pro-caspase-1 and caspase-1 domains are simplified for clarity, 
the CARD domain is actually removed by cleavage, and two heterodimers form with the p20 
and p10 effector domains (p20/10).
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Figure 2. Mechanisms of NLRC4, AIM2 and noncanonical NLRP3 inflammasome activation
(a) NLRC4 inflammasome agonists such as the bacterial needle protein bind directly to 
regions within the NACHT domains of the NAIP subfamily of proteins. hNAIP and 
mNAIP1 bind needle protein, mNAIP2 binds rod protein, and both mNAIP5 and mNAIP6 
bind flagellin. Ligand-bound NAIP proteins then oligomerize with NLRC4 to form a 
caspase-1–activating inflammasome. Though NLRC4 can directly oligomerize with 
caspase-1 through CARD-CARD interactions, ASC is required for caspase-1 activation by 
the NLRC4 inflammasome, possibly through the formation of prion-like filaments (blue) by 
ASC. However, ASC is dispensable for the induction of pyroptosis. Inset shows domain 
arrangement of NLRC4 inflammasome components. NAIP proteins have three N-terminal 
BIR domains. hNAIP, human NAIP; mNAIP, mouse NAIP. (b) The mechanism of AIM2 
inflammasome activation is well defined. The HIN domain of AIM2 directly binds cytosolic 
dsDNA, displacing the PYD and relieving autoinhibition. This allows oligomerization of 
AIM2 PYD with ASC PYD, converting ASC into its prion form. Prion-like filaments of pro-
caspase-1 (violet) are then able to form off of the ASC filaments, inducing caspase-1 
activation. Inset shows domain arrangement of AIM2 inflammasome components. (c) 
Studies have determined that mouse pro-caspase-11 (mPro-caspase-11) and human pro-
caspases-4 and -5 (hPro-caspase-4/5) can directly bind intracellular LPS and activate a 
noncanonical NLRP3 inflammasome. This induces oligomerization of these pro-caspases, 
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leading to their proximity-induced activation. This is sufficient for the induction of 
pyroptosis but not for the processing of pro-IL-1β. However, active mCaspase-11 and 
hCaspase-4 can promote full assembly and activation of the NLRP3 inflammasome 
following a priming signal.
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Figure 3. Mechanisms of NLRP3 inflammasome action in Alzheimer’s disease
In Alzheimer’s disease, CD36 mediates the internalization of soluble amyloid-β and its 
intracellular conversion to fibrillary amyloid-β. This leads to disruption of the 
phagolysosome and activation of the NLRP3 inflammasome due to cathepsin B release. 
However, this does not exclude the possibility that phagocytosis of extracellular fibrillary 
amyloid-β also activates the NLRP3 inflammasome. Cathepsin B inhibition prevents 
amyloid-β–induced NLRP3 activation.
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Figure 4. Mechanism of inflammasome activation in inflammatory disease
(a) In atherosclerosis, free fatty acids (FFA) can prime the NLRP3 inflammasome through 
TLR2-TLR4 signaling. Additionally, oxidized low-density lipoprotein (oxLDL) primes the 
NLRP3 inflammasome through a CD36-TLR4-TLR6 signaling complex. CD36 also 
facilitates the internalization of oxLDL and its intracellular conversion to cholesterol 
crystals, which disrupt the phagolysosome and activate the NLRP3 inflammasome through 
cathepsin release. Phagocytosis of extracellular cholesterol crystals may also contribute to 
inflammasome activation. Cathepsin inhibition prevents the NLRP3 inflammasome 
activation induced by cholesterol crystals. (b) In type 2 diabetes (T2D), the NLRP3 
inflammasome is activated in both islet β-cells and myeloid cells. In β-cells, elevated 
glucose increases thioredoxin (TRX)-interacting protein (TXNIP). Intracellular ROS also 
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causes a conformational change in TXNIP, leading to its dissociation from TRX. TXNIP 
then binds NLRP3 and promotes NLRP3 inflammasome activation. In myeloid cells, the 
endocannabinoid anandamide binds the CB1 receptor to increase the expression of NLRP3, 
ASC and IL1B. Saturated fatty acid (SFA) inhibits intracellular AMP-activated protein 
kinase (AMPK). This decreases autophagy, which leads to an increase in mitochondrial 
ROS (mtROS), a known NLRP3 inflammasome stimulus. CD36 facilitates the 
internalization of soluble islet amyloid polypeptide (IAPP), which is converted 
intracellularly to its amyloid form. This disrupts the phagolysosome and activates the 
NLRP3 inflammasome due to cathepsin release. As the amyloid form of IAPP builds up in 
the pancreatic islets of individuals with T2D, phagocytosis of extracellular amyloid IAPP 
may also contribute to NLRP3 inflammasome activation.
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